SANTA CLARA, CA & DUBAI, Feb 19, 2021 - (ACN Newswire) - Maculus Therapeutix, a preclinical-stage biopharmaceutical company that has developed a SINGLE injection platform to treat wet AMD (Age-related Macular Degeneration) and DME (Diabetic Macular Edema) instead of the standard 8-12 monthly injections, is pleased to welcome Privity FZ LLE as a partner and advisor for upcoming fundraising activities. Maculus plans to raise $3 million at an $8 million valuation for a 12-18 month period, including initial in-vivo animal studies and completion of in-vitro / in-vivo drug elution studies.Maculus achieved the breakthrough using a patented novel tunable biodegradable proprietary product, called MacuBloc. Capable of delivering any FDA approved drug for wet AMD / DME to the site of the disease, with unique suitability for targeted and extended delivery of drugs to the back of the human eyes, MacuBloc offers significant benefits to Wet AMD patients such as a single intravitreal injection that lasts a year rather than the current monthly injections, and a potential reduction in inflammation, infection, doctor visits and total cost of care.Syed H Askari, PhD, Founder, Chief Executive Offic...